AR076374A1 - Azetidinil diamidas como inhibidores de lipasas de monoacil glicerol - Google Patents
Azetidinil diamidas como inhibidores de lipasas de monoacil glicerolInfo
- Publication number
- AR076374A1 AR076374A1 ARP100101335A ARP100101335A AR076374A1 AR 076374 A1 AR076374 A1 AR 076374A1 AR P100101335 A ARP100101335 A AR P100101335A AR P100101335 A ARP100101335 A AR P100101335A AR 076374 A1 AR076374 A1 AR 076374A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- optionally substituted
- group
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Se revelan compuestos, composiciones y métodos para tratar varias enfermedades, síndromes, afecciones y trastornos, incluyendo el dolor. Reivindicacion 1: Un compuesto de formula (1) donde Y y Z se seleccionan independientemente de a) o b) de modo que uno de Y y Z se selecciona del grupo a) y el otro se selecciona del grupo b); el grupo a) es arilo C6-10 sustituido, trifluorometilo, cicloalquilo C3-8, o heteroarilo seleccionado del grupo integrado por tienilo, furanilo, tiazolilo, isotiazolilo, oxazolilo pirrolilo, piridinilo, isoxazolilo, imidazolilo furazan-3-ilo, benzotienilo, tieno[3,2-b]tiofen-2-ilo pirazolilo, triazolilo tetrazolilo, y [1,2,3]tiadiazolilo; donde arilo C6-10 está sustituido con; y el heteroarilo está opcionalmente sustituido con; un sustituyente seleccionado del grupo integrado por fluor, cloro, bromo, alquilo C1-4, ciano alquilcarbonilamino C1-4, y trifluorometilo; el grupo b) es cicloalquilo C5-7-alquilo C1-4 benzofusionado donde cicloalquilo C5-7 está opcionalmente sustituido con 1 a 4 sustituyentes metilo; aril C6-10-alquilo C1-6; aril C6-10-alquenilo C2-6; fenil alquinilo C2-6; cicloalquilo C3-7 opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados del grupo integrado por alquilo C1-3, fluor, cloro, bromo, yodo, trifluorometilo fenilo, y fenilcarbonilo donde el sustituyente fenilo está opcionalmente sustituido con uno a dos sustituyentes seleccionados del grupo integrado por bromo, cloro, fluor, yodo, trifluorometilo trifluorometoxi y trifluorometiltio; fenil-(Q)-metilo donde Q es O o S; donde fenilo está opcionalmente sustituido con trifluorometilo, uno a tres sustituyentes fluor o cloro, o trifluorometoxi; pentadecanjlo; septadeca-8,11-dienilo; nonadeca-4,7,10,13-tetraeno-ilo; nonadecanilo; heptadec-8-eno-ilo; o 1-(4-cianofenil)piperidín-4-ilo; donde el grupo fenilo de fenil alquinilo C2-6; y el arilo C6-10 de aril C6-10-alquilo C1-6 y arilo C6-10-alquenilo C2-6 están cada uno de ellos opcionalmente sustituidos independientemente con uno a dos sustituyentes seleccionados del grupo integrado por alquilo C1-4; alcoxi C1-4, alquiltio C1-4, trifluorometilo; trifluorometoxi; trifluorometiltio, alcoxialquilaminosulfonilo C3-8, alcoxicarbonilo C1-4, alquilcarboniloxi C1-4, NRaRb donde Ra es hidrogeno o alquilo C1-6 y Rb es alquilo C1-6, fenilo, cicloalquilcarbonilo C3-8, cicloalquil C3-8-alquilo C1-2, alquilcarbonilo C1-6 opcionalmente sustituido con uno a tres sustituyentes fluor, arilo C6-10-alquilo C1-2, o fenil alquilcarbonilo C1-2; donde arilo C6-10 y fenilo de Rb están opcionalmente sustituidos con uno a dos sustituyentes seleccionados de alquilo C1-4, trifluorometilo, cloro, o fluor; o Ra y Rb se toman juntos con el átomo de nitrogeno al cual están unidos para formar un anillo heterociclilo de 5 a 8 miembros, opcionalmente sustituido con oxo o alquilo C1-3 y contiene opcionalmente un heteroátomo adicional para formar morfolinilo, tiomorfolinilo, o piperazinilo; y donde dicho anillo heterociclilo está opcionalmente benzofusionado; y, el anillo heterociclilo está opcionalmente sustituido en un átomo de nitrogeno contenido en dicho anillo con alcoxicarbonilo C1-6; feniloxi opcionalmente sustituido con alquilo C1-4, trifluorometilo, o uno a dos sustituyentes cloro; 3,4-dimetilpirazol-1-ilo; ciano; fluor; cloro; bromo; y yodo; s es 0, 1 o 2; siempre que cuando s es 2, R1 se selecciona independientemente del grupo integrado por fenilo, alquilo C1-3, y arilo C6-10-alquilo C1-3; R1 es arilo C6-10, alquilo C1-3, benciloximetilo, hidroxi alquilo C1-3, aminocarbonilo, carboxi, trifluorometilo, ciclopropilo espirofusionado, 3-oxo, o aril alquilo C1-3 o, cuando s es 2 y R1 es alquilo C1-3, los sustituyentes alquilo C1-3 se toman con el anillo piperizinilo para formar un sistema anular 3,8-diaza-biciclo[3.2.1]octanilo o 2,5-diaza-biciclo[2.2.2]octanilo; con la condicion de que un compuesto de formula (1) sea diferente de un compuesto donde Y es tiazol-2-ilo, Z es fenilpropilo, y s es 0; y sus enantiomeros, diastereomeros, y sales aceptables para uso farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17165809P | 2009-04-22 | 2009-04-22 | |
US17164909P | 2009-04-22 | 2009-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076374A1 true AR076374A1 (es) | 2011-06-08 |
Family
ID=42208680
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101338A AR076377A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
ARP100101340A AR076379A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento del dolor, inflamacion y trastornos del snc. |
ARP100101341A AR076380A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasa(mgl), composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades y patologias que incluyen dolor inflamatorio. |
ARP100101335A AR076374A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de lipasas de monoacil glicerol |
ARP100101339A AR076378A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de trastornos inflamatorios asociados al dolor. |
ARP100101343A AR076382A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de trastornos inflamatorios asociados al dolor. |
ARP100101337A AR076376A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
ARP100101342A AR076381A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101338A AR076377A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
ARP100101340A AR076379A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento del dolor, inflamacion y trastornos del snc. |
ARP100101341A AR076380A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasa(mgl), composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades y patologias que incluyen dolor inflamatorio. |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101339A AR076378A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de trastornos inflamatorios asociados al dolor. |
ARP100101343A AR076382A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas inhibidoras de monoacilglicerol lipasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de trastornos inflamatorios asociados al dolor. |
ARP100101337A AR076376A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
ARP100101342A AR076381A1 (es) | 2009-04-22 | 2010-04-22 | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
Country Status (22)
Country | Link |
---|---|
US (16) | US8455476B2 (es) |
EP (8) | EP2421848A1 (es) |
JP (8) | JP2012524802A (es) |
KR (8) | KR101705049B1 (es) |
CN (8) | CN102459230A (es) |
AR (8) | AR076377A1 (es) |
AU (9) | AU2010238736A1 (es) |
BR (8) | BRPI1014284A2 (es) |
CA (8) | CA2759604A1 (es) |
DK (1) | DK2421825T3 (es) |
ES (2) | ES2455744T3 (es) |
HK (2) | HK1170221A1 (es) |
HR (1) | HRP20140295T1 (es) |
IL (8) | IL215773A (es) |
PL (1) | PL2421825T3 (es) |
PT (1) | PT2421825E (es) |
RS (1) | RS53235B (es) |
RU (8) | RU2011147230A (es) |
SI (1) | SI2421825T1 (es) |
SM (1) | SMT201400034B (es) |
TW (8) | TW201103931A (es) |
WO (8) | WO2010124108A1 (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2730506A1 (en) | 2008-07-21 | 2010-01-28 | Novartis Ag | Silicone-containing polymeric materials with hydrolyzable groups |
EP2421848A1 (en) * | 2009-04-22 | 2012-02-29 | Janssen Pharmaceutica N.V. | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
US9082128B2 (en) * | 2009-10-19 | 2015-07-14 | Uniloc Luxembourg S.A. | System and method for tracking and scoring user activities |
WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
US9492439B2 (en) | 2010-03-11 | 2016-11-15 | New York University | Amido compounds as RORγt modulators and uses thereof |
BR112013005141A2 (pt) | 2010-09-03 | 2016-05-10 | Janssen Pharmaceutica Nv | diazetidinil diamida como inibidores de monoacilglicerol lipase |
KR20140001206A (ko) | 2010-09-27 | 2014-01-06 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 옥소피페라진-아제티딘 아미드 및 옥소다이아제핀-아제티딘 아미드 |
CN102417483A (zh) * | 2010-09-27 | 2012-04-18 | 中国药科大学 | 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物 |
US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
CA2815350A1 (en) * | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
RU2013123274A (ru) | 2010-10-22 | 2014-11-27 | Янссен Фармацевтика Нв | Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы |
MX351305B (es) * | 2011-01-20 | 2017-10-09 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides. |
WO2012151448A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
CN103957916A (zh) * | 2011-09-30 | 2014-07-30 | 詹森药业有限公司 | 用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂 |
WO2013049293A1 (en) * | 2011-09-30 | 2013-04-04 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
JP2014528427A (ja) * | 2011-09-30 | 2014-10-27 | ヤンセン ファーマシューティカ エヌ.ベー. | (1−(4−フルオロフェニル)−1h−インドール−5−イル)−(3−(4−(チアゾール−2−カルボニル)ピペラジン−1−イル)アゼチジン−1−イル)メタノンの結晶性塩酸塩、並びに疼痛及び代謝障害の処置におけるその使用 |
LT2800565T (lt) | 2012-01-06 | 2020-07-27 | Lundbeck La Jolla Research Center, Inc. | Karbamato junginiai ir jų gamybos būdai ir panaudojimai |
CN102603485A (zh) * | 2012-02-07 | 2012-07-25 | 北京颖新泰康国际贸易有限公司 | 制备2-甲基-3-苯基苯甲醇的方法 |
TWI562295B (en) | 2012-07-31 | 2016-12-11 | Mediatek Inc | Semiconductor package and method for fabricating base for semiconductor package |
JP6362610B2 (ja) | 2012-11-08 | 2018-07-25 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療用化合物及び組成物並びにpkm2調節剤としてのそれらの使用 |
EP3401314B1 (en) * | 2013-03-15 | 2023-11-08 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
MA38606A1 (fr) | 2013-05-23 | 2017-03-31 | Bayer Pharma AG | Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
MX2016006052A (es) * | 2013-11-12 | 2016-07-18 | Hoffmann La Roche | Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos. |
EP3087067B1 (en) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
JP6640840B2 (ja) * | 2014-09-22 | 2020-02-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 線維症を処置するための方法及び医薬組成物 |
AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
JP6653319B2 (ja) * | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
CA2993018A1 (en) | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
CU20170166A7 (es) | 2015-07-31 | 2018-03-13 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1, 1, 1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Rasの阻害剤をスクリーニングするための方法 |
EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
CA3012791C (en) | 2016-01-27 | 2024-01-23 | Universitat Zurich | Use of gabaa receptor modulators for treatment of itch |
WO2017143283A1 (en) | 2016-02-19 | 2017-08-24 | Abide Therapeutics, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
EP3438109B1 (en) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2017245125B2 (en) | 2016-03-31 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
KR20190104405A (ko) | 2017-01-20 | 2019-09-09 | 화이자 인코포레이티드 | Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체 |
AU2018208848A1 (en) | 2017-01-23 | 2019-07-18 | Pfizer Inc., | Heterocyclic spiro compounds as MAGL inhibitors |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
MX2019014042A (es) | 2017-05-23 | 2020-02-05 | Lundbeck La Jolla Research Center Inc | Inhibidores pirazolicos de magl. |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
TW201900633A (zh) | 2017-05-25 | 2019-01-01 | 美商亞瑞克西斯製藥公司 | Kras之共價抑制劑 |
EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
CN111148746B (zh) | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
CA3093802A1 (en) | 2018-03-13 | 2019-09-19 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
AU2019271123A1 (en) | 2018-05-15 | 2020-11-26 | H. Lundbeck A/S. | MAGL inhibitors |
CN109020890B (zh) * | 2018-09-12 | 2022-02-08 | 南京大学 | 一类饱和脂肪环骈吡唑衍生物的制备及其应用 |
BR112021008741A2 (pt) | 2018-11-09 | 2021-08-10 | Vivace Therapeutics, Inc. | compostos bicíclicos |
CA3120577A1 (en) * | 2018-11-28 | 2020-06-04 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
JP2022529642A (ja) | 2019-04-16 | 2022-06-23 | ビバーチェ セラピューティクス,インク. | 二環式化合物 |
AU2020337938A1 (en) | 2019-08-29 | 2022-03-17 | Array Biopharma Inc. | KRas G12D inhibitors |
US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
EP4034123A4 (en) | 2019-09-24 | 2023-11-01 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
WO2021151014A1 (en) * | 2020-01-23 | 2021-07-29 | Myoforte Therapeutics, Inc. | Pgdh inhibitors and methods of making and using |
EP3875452A1 (en) * | 2020-03-04 | 2021-09-08 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Monoacylglycerol lipase inhibitors |
KR20220158785A (ko) * | 2020-03-26 | 2022-12-01 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아미노사이클로부탄 |
EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
KR20220153888A (ko) * | 2021-05-12 | 2022-11-21 | 에이치케이이노엔 주식회사 | 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도 |
WO2023009618A1 (en) * | 2021-07-28 | 2023-02-02 | Epirium Bio, Inc. | Bicyclic pgdh inhibitors and methods of making and using |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9600235D0 (en) * | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
WO1998037077A1 (en) | 1997-02-24 | 1998-08-27 | Zymogenetics, Inc. | Calcitonin mimetics |
WO1999019297A1 (en) | 1997-10-15 | 1999-04-22 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
TW200300757A (en) * | 2001-11-16 | 2003-06-16 | Schering Corp | Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1 |
US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
PT1522314E (pt) | 2002-06-26 | 2014-06-05 | Ono Pharmaceutical Co | Medicamentos para doenças causadas pela contracção ou dilatação vascular |
EP1581517B1 (en) * | 2002-12-23 | 2007-02-21 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
ATE395062T1 (de) * | 2003-06-10 | 2008-05-15 | Janssen Pharmaceutica Nv | Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen |
EP1702916A1 (en) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | DPP-IV inhibitors |
KR20080036957A (ko) * | 2005-06-23 | 2008-04-29 | 아스트라제네카 아베 | 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체 |
JP2009521451A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとして有用な置換アニリン誘導体 |
DE102006016023A1 (de) * | 2006-04-05 | 2007-10-11 | Basf Ag | Funktionale Expression von Triacylglycerol-Lipasen |
CN101528712B (zh) | 2006-08-26 | 2013-10-30 | Abbvie德国有限责任两合公司 | 取代的苯并咪唑酮衍生物、包含它们的药物以及其用途 |
FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
FR2915199B1 (fr) | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
US9271962B2 (en) | 2008-03-17 | 2016-03-01 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
JP5715945B2 (ja) | 2008-04-25 | 2015-05-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | モノアシルグリセロールリパーゼ(mgll)の結晶構造 |
EP2180048B1 (en) | 2008-10-09 | 2014-12-17 | Janssen Pharmaceutica N.V. | Alternative crystal form of monoacylglycerol lipase (MGLL) |
US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
RU2558141C2 (ru) | 2009-04-22 | 2015-07-27 | Янссен Фармацевтика Нв | Гетероароматические и ароматические пиперазинилазетидиниламиды в качестве ингибиторов моноацилглицеринлипазы |
EP2421848A1 (en) * | 2009-04-22 | 2012-02-29 | Janssen Pharmaceutica N.V. | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
DE102012109699A1 (de) * | 2012-10-11 | 2014-04-17 | Pavel Abdulkin | Verfahren zum Bereitstellen einer Gold-Nano-Hülle um kleine, magnetische Partikel im Submikrometerbereich und so erhaltene Partikel |
-
2010
- 2010-04-22 EP EP10715461A patent/EP2421848A1/en not_active Withdrawn
- 2010-04-22 CN CN2010800287478A patent/CN102459230A/zh active Pending
- 2010-04-22 EP EP10716203A patent/EP2421851A1/en not_active Withdrawn
- 2010-04-22 ES ES10716205.9T patent/ES2455744T3/es active Active
- 2010-04-22 AU AU2010238736A patent/AU2010238736A1/en not_active Abandoned
- 2010-04-22 KR KR1020117027691A patent/KR101705049B1/ko active IP Right Grant
- 2010-04-22 AU AU2010239188A patent/AU2010239188B2/en not_active Ceased
- 2010-04-22 TW TW099112750A patent/TW201103931A/zh unknown
- 2010-04-22 WO PCT/US2010/032082 patent/WO2010124108A1/en active Application Filing
- 2010-04-22 JP JP2012507382A patent/JP2012524802A/ja not_active Withdrawn
- 2010-04-22 JP JP2012507387A patent/JP5733840B2/ja not_active Expired - Fee Related
- 2010-04-22 AU AU2010238738A patent/AU2010238738A1/en not_active Abandoned
- 2010-04-22 AU AU2010238732A patent/AU2010238732B2/en not_active Ceased
- 2010-04-22 PT PT107162059T patent/PT2421825E/pt unknown
- 2010-04-22 RU RU2011147230/04A patent/RU2011147230A/ru not_active Application Discontinuation
- 2010-04-22 US US12/765,103 patent/US8455476B2/en active Active
- 2010-04-22 RU RU2011147233/04A patent/RU2549547C2/ru not_active IP Right Cessation
- 2010-04-22 AR ARP100101338A patent/AR076377A1/es not_active Application Discontinuation
- 2010-04-22 DK DK10716205.9T patent/DK2421825T3/da active
- 2010-04-22 CA CA2759604A patent/CA2759604A1/en not_active Abandoned
- 2010-04-22 KR KR1020117027341A patent/KR20110137831A/ko not_active Application Discontinuation
- 2010-04-22 TW TW099112747A patent/TWI483940B/zh not_active IP Right Cessation
- 2010-04-22 BR BRPI1014284A patent/BRPI1014284A2/pt not_active IP Right Cessation
- 2010-04-22 AR ARP100101340A patent/AR076379A1/es not_active Application Discontinuation
- 2010-04-22 BR BRPI1014281A patent/BRPI1014281A2/pt not_active IP Right Cessation
- 2010-04-22 EP EP10717365A patent/EP2421847A1/en not_active Withdrawn
- 2010-04-22 BR BRPI1015238A patent/BRPI1015238A2/pt not_active IP Right Cessation
- 2010-04-22 KR KR1020117027654A patent/KR101705697B1/ko active IP Right Grant
- 2010-04-22 WO PCT/US2010/032089 patent/WO2010124114A1/en active Application Filing
- 2010-04-22 CA CA2759505A patent/CA2759505A1/en not_active Abandoned
- 2010-04-22 CN CN2010800287586A patent/CN102459255A/zh active Pending
- 2010-04-22 RU RU2011147206/04A patent/RU2569298C2/ru not_active IP Right Cessation
- 2010-04-22 RU RU2011147200/04A patent/RU2011147200A/ru not_active Application Discontinuation
- 2010-04-22 BR BRPI1013540-5A patent/BRPI1013540A2/pt not_active IP Right Cessation
- 2010-04-22 AR ARP100101341A patent/AR076380A1/es not_active Application Discontinuation
- 2010-04-22 TW TW099112748A patent/TW201105655A/zh unknown
- 2010-04-22 KR KR1020117027713A patent/KR20120034623A/ko not_active Application Discontinuation
- 2010-04-22 US US12/765,420 patent/US8362000B2/en active Active
- 2010-04-22 BR BRPI1013545A patent/BRPI1013545A2/pt not_active IP Right Cessation
- 2010-04-22 BR BRPI1014885A patent/BRPI1014885A8/pt not_active Application Discontinuation
- 2010-04-22 RU RU2011147207/04A patent/RU2011147207A/ru not_active Application Discontinuation
- 2010-04-22 US US12/765,254 patent/US8399454B2/en active Active
- 2010-04-22 RU RU2011147236/04A patent/RU2011147236A/ru not_active Application Discontinuation
- 2010-04-22 EP EP10715456A patent/EP2421860A1/en not_active Withdrawn
- 2010-04-22 BR BRPI1014876A patent/BRPI1014876A2/pt not_active IP Right Cessation
- 2010-04-22 CN CN201080028749.7A patent/CN102459167B/zh not_active Expired - Fee Related
- 2010-04-22 BR BRPI1013538A patent/BRPI1013538A2/pt not_active IP Right Cessation
- 2010-04-22 US US12/765,179 patent/US8450303B2/en active Active
- 2010-04-22 CN CN2010800287603A patent/CN102548982A/zh active Pending
- 2010-04-22 KR KR1020117027324A patent/KR20120034616A/ko not_active Application Discontinuation
- 2010-04-22 JP JP2012507389A patent/JP2012524805A/ja not_active Withdrawn
- 2010-04-22 RU RU2011147185/04A patent/RU2011147185A/ru not_active Application Discontinuation
- 2010-04-22 SI SI201030535T patent/SI2421825T1/sl unknown
- 2010-04-22 CA CA2759713A patent/CA2759713A1/en not_active Abandoned
- 2010-04-22 JP JP2012507377A patent/JP2012524800A/ja not_active Withdrawn
- 2010-04-22 WO PCT/US2010/032049 patent/WO2010124086A1/en active Application Filing
- 2010-04-22 KR KR1020117027313A patent/KR20120034615A/ko not_active Application Discontinuation
- 2010-04-22 EP EP10715460A patent/EP2421824A1/en not_active Withdrawn
- 2010-04-22 CN CN201080028726.6A patent/CN102459166B/zh not_active Expired - Fee Related
- 2010-04-22 CN CN2010800287590A patent/CN102459228A/zh active Pending
- 2010-04-22 KR KR1020117027340A patent/KR20120035146A/ko not_active Application Discontinuation
- 2010-04-22 AR ARP100101335A patent/AR076374A1/es not_active Application Discontinuation
- 2010-04-22 AR ARP100101339A patent/AR076378A1/es unknown
- 2010-04-22 US US12/765,076 patent/US8367653B2/en active Active
- 2010-04-22 WO PCT/US2010/032095 patent/WO2010124119A1/en active Application Filing
- 2010-04-22 JP JP2012507392A patent/JP2012524807A/ja not_active Withdrawn
- 2010-04-22 ES ES10715457.7T patent/ES2538326T3/es active Active
- 2010-04-22 US US12/765,018 patent/US8426401B2/en active Active
- 2010-04-22 JP JP2012507388A patent/JP2012524804A/ja not_active Withdrawn
- 2010-04-22 JP JP2012507378A patent/JP5649644B2/ja not_active Expired - Fee Related
- 2010-04-22 TW TW099112752A patent/TW201105665A/zh unknown
- 2010-04-22 WO PCT/US2010/032092 patent/WO2010124116A1/en active Application Filing
- 2010-04-22 CA CA2759614A patent/CA2759614C/en not_active Expired - Fee Related
- 2010-04-22 TW TW099112751A patent/TW201116280A/zh unknown
- 2010-04-22 WO PCT/US2010/032045 patent/WO2010124082A1/en active Application Filing
- 2010-04-22 JP JP2012507390A patent/JP2012524806A/ja not_active Withdrawn
- 2010-04-22 KR KR1020117027334A patent/KR20120034617A/ko not_active Application Discontinuation
- 2010-04-22 CN CN2010800287463A patent/CN102803210A/zh active Pending
- 2010-04-22 AU AU2010239204A patent/AU2010239204A1/en not_active Abandoned
- 2010-04-22 EP EP10716205.9A patent/EP2421825B9/en active Active
- 2010-04-22 EP EP10715457.7A patent/EP2421823B1/en active Active
- 2010-04-22 TW TW099112746A patent/TW201105654A/zh unknown
- 2010-04-22 WO PCT/US2010/032068 patent/WO2010124102A1/en active Application Filing
- 2010-04-22 AU AU2010238743A patent/AU2010238743A1/en not_active Abandoned
- 2010-04-22 AU AU2010238740A patent/AU2010238740A1/en not_active Abandoned
- 2010-04-22 US US12/765,048 patent/US8445477B2/en active Active
- 2010-04-22 CA CA2759547A patent/CA2759547A1/en not_active Abandoned
- 2010-04-22 CA CA2759621A patent/CA2759621C/en not_active Expired - Fee Related
- 2010-04-22 CN CN2010800288396A patent/CN102459240A/zh active Pending
- 2010-04-22 EP EP10716672A patent/EP2421856A1/en not_active Withdrawn
- 2010-04-22 RS RS20140136A patent/RS53235B/en unknown
- 2010-04-22 AR ARP100101343A patent/AR076382A1/es not_active Application Discontinuation
- 2010-04-22 TW TW099112753A patent/TW201103932A/zh unknown
- 2010-04-22 CA CA2759697A patent/CA2759697A1/en not_active Abandoned
- 2010-04-22 PL PL10716205T patent/PL2421825T3/pl unknown
- 2010-04-22 AU AU2010239184A patent/AU2010239184A1/en not_active Abandoned
- 2010-04-22 CA CA2759501A patent/CA2759501A1/en not_active Abandoned
- 2010-04-22 TW TW099112749A patent/TWI465446B/zh not_active IP Right Cessation
- 2010-04-22 US US12/765,487 patent/US8362001B2/en active Active
- 2010-04-22 AR ARP100101337A patent/AR076376A1/es unknown
- 2010-04-22 WO PCT/US2010/032086 patent/WO2010124112A1/en active Application Filing
- 2010-04-22 RU RU2011147181/04A patent/RU2011147181A/ru not_active Application Discontinuation
- 2010-04-22 AR ARP100101342A patent/AR076381A1/es not_active Application Discontinuation
-
2011
- 2011-10-23 IL IL215773A patent/IL215773A/en not_active IP Right Cessation
- 2011-10-23 IL IL215798A patent/IL215798A0/en unknown
- 2011-10-23 IL IL215786A patent/IL215786A0/en unknown
- 2011-10-23 IL IL215787A patent/IL215787A0/en unknown
- 2011-10-23 IL IL215775A patent/IL215775A0/en unknown
- 2011-10-23 IL IL215781A patent/IL215781A0/en unknown
- 2011-10-23 IL IL215780A patent/IL215780A/en not_active IP Right Cessation
- 2011-10-23 IL IL215785A patent/IL215785A0/en unknown
-
2012
- 2012-10-29 HK HK12110778.3A patent/HK1170221A1/xx not_active IP Right Cessation
- 2012-10-30 HK HK12110891.5A patent/HK1170228A1/xx not_active IP Right Cessation
- 2012-12-17 US US13/716,705 patent/US8604017B2/en active Active
- 2012-12-18 US US13/718,056 patent/US8741887B2/en active Active
- 2012-12-18 US US13/718,257 patent/US8623858B2/en active Active
-
2013
- 2013-01-25 US US13/749,846 patent/US8722658B2/en active Active
- 2013-03-18 US US13/845,982 patent/US8697683B2/en active Active
- 2013-04-22 US US13/867,372 patent/US8962607B2/en active Active
- 2013-04-29 US US13/872,427 patent/US8697684B2/en active Active
- 2013-05-01 US US13/874,835 patent/US8691805B2/en active Active
-
2014
- 2014-03-20 SM SM201400034T patent/SMT201400034B/xx unknown
- 2014-03-27 HR HRP20140295AT patent/HRP20140295T1/hr unknown
-
2016
- 2016-03-03 AU AU2016201405A patent/AU2016201405A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076374A1 (es) | Azetidinil diamidas como inhibidores de lipasas de monoacil glicerol | |
PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
PE20160859A1 (es) | Inhibidores de la quinasa reguladora de la senal de apoptosis | |
HRP20180861T1 (hr) | Kristalni oblici 1-(5′-(5-(3,5-diklor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-3′h-spiro[azetidin-3,1′-izobenzofuran]-1-il)-2-(metilsulfonil)etanona | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
AR081587A1 (es) | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR063723A1 (es) | 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios | |
AR092790A1 (es) | Derivados bencimidazolicos del acido hidroxamico | |
AR076002A1 (es) | Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
PE20141358A1 (es) | Polimorfos de inhibidores de cinasas | |
DK2076501T3 (da) | Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre | |
AR076765A1 (es) | Compuestos antivirales | |
DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
AR069212A1 (es) | 1h-2-tia-1,5,8-triaza-naftalen-2,2-dioxidos con actividad herbicida | |
AR105544A1 (es) | Compuestos de n-carboxamida cíclica útiles como herbicidas | |
AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
AR050516A1 (es) | Bifeniltiazolcarboxamidas. composiciones antimicrobianas | |
AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |